Medscape: Empagliflozin Rapidly Improves Acute Heart Failure Symptoms in Hospitalized Patients

Treatment of patients acutely hospitalized for heart failure with the SGLT2 inhibitor empagliflozin led to a rapid incremental increase in patient well-being, compared with control patients who received placebo, that appeared after 2 weeks on treatment in a secondary analysis from 530 randomized patients in the EMPULSE trial.

To Mikhail N. Kosiborod, MD, a coinvestigator for EMPULSE who presented new analysis at the annual scientific sessions of the American College of Cardiology, the message from the quick response of acutely hospitalized patients to empagliflozin was clear: “Use these medications, SGLT2 [sodium-glucose cotransporter 2] inhibitors, as early as possible. We’ve seen with other medications that if they are not prescribed during hospitalization it’s unlikely to happen post discharge,” said Kosiborod, a cardiologist and codirector of the Saint Luke's Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute in Kansas City, Mo.

“To our knowledge, the very early improvement in the Kansas City Cardiomyopathy Questionnaire [KCCQ] score – a well-known predictor of cardiovascular death and heart failure readmissions – that we observed with empagliflozin at 15 days is the first such observation, and if corroborated by future studies would suggest that initiation of SGLT2 inhibitors during hospitalization for acute heart failure may be a tool for improving the quality of hospital-to-home transitions,” wrote Kosiborod and his associates in the published version of their report that appeared concurrently with his report at the meeting.

Read the full Medscape article: Empagliflozin Rapidly Improves Acute Heart Failure Symptoms in Hospitalized Patients

Related Content

Apr. 14, 2022
HealthDay: Empagliflozin Offers Clinical Benefit in Heart Failure
A new study by Dr. Kosiborod and colleagues found clinical benefits in treatment with empagliflozin for patients hospitalized with acute heart failure.
Apr. 8, 2022
TCTMD: Quality of Life Gains Within 15 Days in Acute Heart Failure with Empagliflozin: EMPULSE Analysis
A secondary analysis of the EMPULSE trial provides more context to the quality-of-life benefits of the early initiation of empagliflozin in patients hospitalized with acute decompensated heart failure.
Apr. 8, 2022
Healio: Empagliflozin Benefits Acute HF Regardless of Baseline Impairment: EMPULSE
Study shows patients with acute heart failure assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo.